Later Line Therapeutic Decisions in Metastatic HCC
Later Line Therapeutic Decisions in Metastatic HCC
February 2014
- A 63-year old male with HBV
- ECOG=0
- Child-Pugh A; platelet count 230,000 cells/mcL
- Bilirubin 1.0 mg/dL; Albumin 3.5 g/dL
- CT scan revealed liver lesions, 1 is 2-cm; 1 is 5-cm both in the right lobe
- No extrahepatic disease
- Biopsy confirmed HCC diagnosis
- AFP=5400 IU/ml
- Tumors were resected with RO margin
August 2016
- Imaging showed recurrence in the liver, metastatic disease in the lungs
- Therapy was initiated with sorafenib 400 mg BID
- Therapy was well-tolerated
April 2017
- Radiographic progression with multiple lung metastases
- ECOG=0
- Therapy with regorafenib initiated at 160 mg
- Starting dose was well-tolerated, patient experienced some fatigue
Recent Videos
Related Content
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024Article
During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
